|
Press Releases |
|
|
|
Wednesday, September 5, 2018 |
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
Friday, July 27, 2018 |
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
Friday, June 22, 2018 |
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
Wednesday, June 6, 2018 |
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
Friday, May 4, 2018 |
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
Wednesday, April 18, 2018 |
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
Wednesday, April 11, 2018 |
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
Friday, March 30, 2018 |
|
Nanobiotix 2017 Annual Results |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
Monday, January 22, 2018 |
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
Thursday, January 11, 2018 |
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 23:06: JST
|
|
|
Graid Technology Announces Software Update, Delivers Enhanced Levels of Data Integrity and Business Continuity
Apr 23, 2024 23:00 HKT/SGT
|
|
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 22:00 HKT/SGT
|
|
|
GA-ASI Mojave Lights Up the Yuma Desert in Live-Fire Demonstration
Apr 23, 2024 20:00 HKT/SGT
|
|
|
2024 U.S. Open Polo Championship(R) Closes Out Historic High-Goal Season at the Sport's Premier Destination in Palm Beach County, Florida
Apr 23, 2024 20:00 HKT/SGT
|
|
|
HKTDC Home InStyle, Fashion InStyle forge global business opportunities
Apr 23, 2024 19:00 HKT/SGT
|
|
|
Dubai Sets the Stage for Digital Innovation: Unveiling the Inaugural Digital Transformation Summit
Apr 23, 2024 18:56: JST
|
|
|
Masverse Unveils Groundbreaking Blockchain Platform
Apr 23, 2024 18:00 HKT/SGT
|
|
|
Dubai Sets the Stage for Digital Innovation: Unveiling the Inaugural Digital Transformation Summit
Apr 23, 2024 17:56 HKT/SGT
|
|
|
New Contaminants, Food Testing & More: analytica Convention 2024 Focuses on Vietnam's Laboratory Needs
Apr 23, 2024 17:00: JST
|
|
|
New Contaminants, Food Testing & More: analytica Convention 2024 Focuses on Vietnam's Laboratory Needs
Apr 23, 2024 16:00 HKT/SGT
|
|
|
多元产品夯实核心竞争力 泛娱乐产品龙头卡游拟赴港IPO
Apr 23, 2024 15:25 HKT/SGT
|
|
|
多元產品夯實核心競爭力 泛娛樂產品龍頭卡游擬赴港IPO
Apr 23, 2024 15:20 HKT/SGT
|
|
|
Singapore Unveils Its First Live Painting Event Featuring ADHD Artists, Inspired by 'Collide' by Tay Guan Hin"
Apr 23, 2024 14:28 HKT/SGT
|
|
|
EM2AI Revolutionising the Dental Industry: New AI Products Promise Transparent Treatment Plans for Patients
Apr 23, 2024 14:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|